Article PDF first page preview

First page of Surveillance and treatment of Barrett’s Esophagus: results from a Portuguese tertiary center

Introduction: Barrett’s esophagus (BE) is a premalignant condition that requires surveillance, in order to diagnose and treat dysplasia, improving survival. Results from surveillance and endoscopic treatment are well-described in different populations. This is the first evaluation of the outcomes of endoscopic resection and ablation of BE patients in a Portuguese center. Methods: This is a single-center retrospective cohort study analyzing the results of endoscopic surveillance and treatment of patients with BE between January 2004 and September 2024. The following outcomes were evaluated: detection of dysplasia and/or visible lesions; rate of curative endoscopic resection; rate of BE refractory to ablation; adverse event (AE) rates of endoscopic resection and ablation; BE-related mortality and survival. Results: Eighty-nine patients were followed for a median of 3 years (IQR 1-6). A total of 37 lesions were identified, and treated with endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) and other modalities in 76%, 16% and 8% of patients respectively, with curative resection and AE rates of 86% (95% CI 67%-96%) and 11% (95% CI 2%-28%) for EMR, and 67% (95% CI 22%-96%) and 17% (95% CI 0%-64%) for ESD, respectively. A response rate of 97% was observed in 33 patients submitted to mucosal ablation, with one patient presenting refractory disease and one patient showing recurrence of intestinal metaplasia. One patient died of BE-related neoplasia. Conclusion: Our study shows results of BE treatment generally comparable to published literature, in a low-prevalence country. A high curative resection and a high success rate of mucosal ablation was achieved, with low refractory and recurrent disease.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial